Covered recipient · General Payments record
JENNIFER L WIT
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2021–2024
$3,141.80
- Reported across 136 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $698.02 | 33 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $457.43 | 19 |
| Novo Nordisk AS | $70.09 | 3 |
| Phathom Pharmaceuticals, Inc. | $32.02 | 2 |
| Amgen Inc. | $28.40 | 2 |
| PFIZER INC. | $18.26 | 1 |
| Merck Sharp & Dohme Corporation | $17.35 | 1 |
| Exact Sciences Corporation | $16.37 | 1 |
| Lilly USA, LLC | $15.54 | 1 |
| Acerta Pharma LLC | $14.69 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $14.42 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.45 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (33)
Sorted by paying entity, then date · as published by CMS
Program year 2024 202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.38 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350518 | CMS |
| ABBVIE INC. | $6.28 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350520 | CMS |
| ABBVIE INC. | $19.65 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350522 | CMS |
| ABBVIE INC. | $23.44 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350524 | CMS |
| ABBVIE INC. | $100.24 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350526 | CMS |
| ABBVIE INC. | $7.92 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350528 | CMS |
| ABBVIE INC. | $21.14 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350530 | CMS |
| ABBVIE INC. | $13.23 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350532 | CMS |
| ABBVIE INC. | $114.36 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350534 | CMS |
| ABBVIE INC. | $2.50 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350536 | CMS |
| ABBVIE INC. | $15.71 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350538 | CMS |
| ABBVIE INC. | $7.58 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350540 | CMS |
| ABBVIE INC. | $11.80 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350542 | CMS |
| ABBVIE INC. | $10.90 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350544 | CMS |
| ABBVIE INC. | $9.39 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350546 | CMS |
| ABBVIE INC. | $19.78 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350548 | CMS |
| ABBVIE INC. | $1.33 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350550 | CMS |
| ABBVIE INC. | $19.11 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350552 | CMS |
| ABBVIE INC. | $32.69 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106350554 | CMS |
| Amgen Inc. | $13.28 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117720518 | CMS |
| Amgen Inc. | $15.12 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117720520 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.69 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1123310804 | CMS |
| Exact Sciences Corporation | $16.37 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128381528 | CMS |
| Lilly USA, LLC | $15.54 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135717550 | CMS |
| Merck Sharp & Dohme LLC | $17.35 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141921306 | CMS |
| Novo Nordisk Inc | $18.20 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108567463 | CMS |
| Novo Nordisk Inc | $27.71 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108573524 | CMS |
| Novo Nordisk Inc | $24.18 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108565207 | CMS |
| PFIZER INC. | $18.26 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131557243 | CMS |
| Phathom Pharmaceuticals, Inc. | $18.10 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151216491 | CMS |
| Phathom Pharmaceuticals, Inc. | $13.92 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151216493 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.45 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153546793 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $14.42 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137845536 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.